Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: Results of a phase II study

Cancer

Volumn 104, Issue 3, 2005, Pages 611-617

  Siehl, Jan M ^a,b   Thiel, Eckhard ^a   Schmittel, Alexander ^a   Hütter, Gero ^a   Deckert, Peter M ^a   Szelényi, Hubert ^a   Keilholz, Ulrich ^a  

^a Medizinische Klinik I   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Advanced soft tissue sarcoma; Ifosfamide; Liposomal daunorubicin; Phase II study

Indexed keywords

DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; LIPOSOME; MESNA;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MALE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DAUNORUBICIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 22544453003     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21211     Document Type: Article

References (38)

1. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et.al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999;17:150-157.
2. Pinedo HM, Bramwell VH, Mouridsen HT, et al. Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer. 1984;53:1825-1832.
3. Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987;23:1477-1483.
4. Schutte J, Mouridsen HT, Stewart W, et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 1990;26:558-561.
5. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995;13:1537-1545.
6. Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1993;11:15-21.
7. Dombernovski P, Mouridsen H, Nielsen OS, et al. A phase III trial comparing Adriamycin versus two schedules of high dose epirubicin in advanced soft tissue sarcomas [abstract]. Proc Am Soc Clin Oncol. 1995;14:515.
8. Tursz T, Verweij J, Judson I, et al. Is high dose chemotherapy of interest in advanced soft tissue sarcomas? An EORTC randomized phase III trial [abstract]. Proc Am Soc Clin Oncol. 1996;15:337.
9. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-1275.
10. Antman KH, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276-1285.
11. Bui BN, Chevreau C, Demaille MC, et al. A randomized phase III study of MAID vs intensified MAID in patients with advanced soft tissue sarcomas [abstract]. Proc Am Soc Clin Oncol. 1998;17:516a.
12. Yap BS, Sincovics JG, Burgess MA, et al. The curability of advanced soft tissue sarcomas in adult with chemotherapy [abstract]. Proc Am Soc Clin Oncol. 1983;1:239.
13. Blay JY, van Glabbeke M, Verweij J, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer. 2003;39:64-69.
14. Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist. 2002;7:348-359.
15. O'Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G. Phase II evaluation of Adriamycin in human neoplasia. Cancer. 1973;32:1-8.
16. Stuart-Harris RC, Harper PG, Parsons CA, et al. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol. 1983;11:69-72.
17. O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of Adriamycin in human neoplasia. Cancer. 1977; 39:1940-1948.
18. Langer R. Drug delivery and targeting. Nature. 1998; 392(6679 Suppl):5-10.
19. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992;52:891-896.
20. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX(TM)/Doxil((R))) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449.
21. D'Agostino G, Ferrandina G, Ludovisi M, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89:1180-1184.
22. Escobar PF, Markman M, Zanotti K, Webster K, Belinson J. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol. 2003;129:651-654.
23. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992;52:3255-3261.
24. O'Byrne KJ, Thomas AL, Sharma RA, et al. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer. 2002;87:15-20.
25. Guaglianone P, Chan K, DelaFlor-Weiss E, et al. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs. 1994;12:103-110.
26. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996;14:2353-2364.
27. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37:870-877.
28. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest. 2003;21:167-176.
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
30. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989;7:126-131.
31. Enzinger FM, Weiss SW, editors. Soft tissue tumors. Washington, DC: C.V. Mosby Company, 1988.
32. Lack EE, Steinberg SM, White DE, et al. Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas. J Surg Oncol. 1989;41:263-273.
33. Verrill MW, Judson IR, Wiltshaw E, et al. The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. Ann Oncol. 1997;8:1099-1105.
34. Bacci G, Ferrari S, Comandone A, et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol. 2000;39:111-116.
35. Martin RC 2nd, Brennan MF. Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: predictors of survival? Arch Surg. 2003;138:281-285.
36. Lenaz L, Page JA. Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat Rev. 1976;3:111-120.
37. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol. 1995;13:996-1003.
38. Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjian H. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs. 1999;17:81-87.